Condition Directory

ALS clinical trials

Directory of U.S. ClinicalTrials.gov public records for ALS. Browse ALS recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.

By Clinical Trials Finder Guidance last reviewed June 10, 2026 Data synced October 21, 2026 Report an issue

ClinicalTrials.gov public records Last synced Oct 21, 2026, 11:18 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

487

Shown on this page

Current sort

How ALS studies are organized in the registry

Listings appear under both the abbreviation ALS and the full name “amyotrophic lateral sclerosis,” and some related records use “motor neuron disease.” The total volume is modest, so browsing the unfiltered list is practical; expanded-access records also appear in this condition and are labeled as such in the study-type field.

Terms that often appear in related listings

amyotrophic lateral sclerosis motor neuron disease SOD1 expanded access

These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.

Showing 157–168 of 487 matching trials for ALS.

Live ClinicalTrials.gov results.

Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search

Conditions: Amyotrophic Lateral Sclerosis
Interventions: DNL747, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 21 Years to 80 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 2
States / cities: Orlando, Florida • Salt Lake City, Utah

Conditions: Amyotrophic Lateral Sclerosis
Interventions: Masitinib (6.0), Riluzole, Placebo, Masitinib (4.5); Drug
Lead sponsor: AB Science; Industry
Eligibility: 18 Years to 81 Years
Enrollment: 495 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 6
States / cities: Birmingham, Alabama • Los Angeles, California • Lexington, Kentucky + 3 more

Conditions: Amyotrophic Lateral Sclerosis (ALS)
Interventions: SNUG01; Drug
Lead sponsor: SineuGene Therapeutics Co., Ltd.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Upper Extremity Impairments, Cerebral Palsy (CP), ALS - Amyotrophic Lateral Sclerosis, Rett Syndrome
Interventions: One-week trial of Obi Medical device, which provides robotic assistance with feeding to persons with upper extremity impairments who are unable to self-feed in the traditional manner using utensils; Device
Lead sponsor: Desin LLC; Industry
Eligibility: 5 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Amyotrophic Lateral Sclerosis
Interventions: Trehalose; Drug
Lead sponsor: Seelos Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
U.S. locations: 21
States / cities: Phoenix, Arizona • Orange, California • San Francisco, California + 16 more

Conditions: ALS Caused by Superoxide Dismutase 1 (SOD1) Mutation
Interventions: Tofersen; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years and older
Enrollment: 139 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 16
States / cities: Phoenix, Arizona • La Jolla, California • San Francisco, California + 13 more

Conditions: Parkinson Disease, Amyotrophic Lateral Sclerosis
Interventions: AMDX2011P; Drug
Lead sponsor: Amydis Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 2
States / cities: Newport Beach, California • Pasadena, California

Conditions: Amyotrophic Lateral Sclerosis
Interventions: IC14; Biological
Lead sponsor: Implicit Bioscience; Industry
Eligibility: 18 Years and older
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Amyotrophic Lateral Sclerosis
Interventions: CNS10-NPC-GDNF; Biological
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Amyotrophic Lateral Sclerosis, ALS
Interventions: AMX0035; Drug
Lead sponsor: Amylyx Pharmaceuticals Inc.; Industry
Eligibility: Not listed
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 24
States / cities: Phoenix, Arizona • Orange, California • San Francisco, California + 20 more

Conditions: Amyotrophic Lateral Sclerosis, Myasthenia Gravis
Interventions: yogic breathing exercise; Behavioral
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 90 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Amyotrophic Lateral Sclerosis (ALS)
Interventions: Transcranial Direct Current Stimulation (tDCS), Sham tDCS + anodal tDCS; Other
Lead sponsor: University of Illinois at Chicago; Other
Eligibility: 18 Years to 80 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Chicago, Illinois

About this ALS clinical trials directory page

What this page lists: U.S. ClinicalTrials.gov public records that list ALS as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results: Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within ALS.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

ALS clinical trials

How ALS studies are organized in the registry

Filter and sort this condition

Live official records

Study to Evaluate DNL747 in Subjects With Amyotrophic Lateral Sclerosis

Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients

A Phase Ⅰ/Ⅱa Study of SNUG01 in Adult Subjects With ALS

Obi Medical Robot: Evaluating Effectiveness Related to Usability

Intermediate-Sized Expanded Access Study

Long-Term Evaluation of BIIB067 (Tofersen)

Study of AMDX-2011P as a Retinal Tracer in Subjects With Neurodegenerative Diseases Associated With Amyloidogenic Proteinopathy

IC14 for ALS Patients Expanded Access

CNS10-NPC-GDNF Delivered to the Motor Cortex for ALS

Open Label Extension Study of AMX0035 in Patients With ALS

Yogic Breathing Exercise for People With Amyotrophic Lateral Sclerosis

Remotely Supervised tDCS for Slowing ALS Disease Progression

About this ALS clinical trials directory page